Screener
KURE vs KEMX
KraneShares MSCI All China Health Care Index ETF vs KraneShares MSCI Emerging Markets ex China Index ETF
Key differences
- KEMX costs 0.41% less per year.
- Over the last 3 years, KEMX has delivered higher annualized returns.
Side-by-side comparison
| KURE | KEMX | |
|---|---|---|
| Annual cost (TER) | 0.65% | 0.24% |
| Fund size (AUM) | $82M | $118M |
| Since | 2018 | 2019 |
| Dividend yield | 4.14% | 2.67% |
| Asset class | equity | equity |
| Region | emerging markets | — |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +3.5% | +74.0% |
| CAGR 3Y | -4.9% | +29.4% |
| CAGR 5Y | -14.7% | +14.0% |
| Sharpe 3Y | -0.14 | 1.30 |
| Volatility 1Y | 26.25% | 22.26% |
| Max drawdown | -68.53% | -38.80% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to KURE and KEMX
Explore further